In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e21599-e21599
Abstract:
e21599 Background: Extramammary Paget’s disease (EMPD) is very rare disease. Due to its rarity, there have been few clinical trials and no standard therapy to date. In this multicenter retrospective study, we investigated the treatment patterns and outcomes of Korean patients with advanced/metastatic extramammary Paget’s disease. Methods: As a retrospective multicenter study, we searched the medical record from 15 centers participating Rare Cancer Committee in Korean Cancer Study Group (KCSG). Results: A total of 54 patients were identified, and 11 patients who refused or did not receive treatments were excluded. In remaining 43 patients, 9 patients received locoregional therapy as first-line treatment and 34 patients initially received systemic chemotherapy. In 34 patients who received systemic chemotherapy as first-line treatment, cisplatin plus 5-fluorouracil was the most frequently used chemotherapy regimen (n = 19). Cisplatin plus 5-fluorouracil regimen achieved an objective response rate of 42.1% and a median PFS of 7.9 months. The next frequently used chemotherapy regimen was docetaxel monotherapy (n = 6). Docetaxel monotherapy achieved an objective response rate of 50.0% and a median PFS of 8.5 months. There was no statistical difference between the two treatments (p = 0.29). Two patients received trastuzumab plus paclitaxel regimen as first-line therapy. Both obtained partial response, with PFS of 13.0+ and 8.2+ months respectively. Seventeen patients received second-line chemotherapy for disease progression. In 17 patients who received systemic chemotherapy as second-line treatment, docetaxel monotherapy was the most frequently used chemotherapy regimen (n = 6). Docetaxel monotherapy achieved an objective response rate of 50.0% and a median PFS of 4.5 months. Two patients received trastuzumab plus paclitaxel regimen as second-line therapy. Both obtained partial response, with PFS of 8.7 and 12.7 months respectively. In 4 patients received trastuzumab plus paclitaxel during first- and second-line chemotherapy, trastuzumab plus paclitaxel achieved an objective response rate of 100% and a median PFS of 10.7+ months. Overall, most patients with advanced/metastatic extramammary Paget’s disease could receive up to median two lines of chemotherapy and obtained median overall survival of 20.8 months. Conclusions: Due to its rarity, advanced or metastatic EMPD still has no established standard treatment. Results of our study indicate that there is no significant difference between cisplatin plus 5-fluorouracil and docetaxel treatment in the first-line treatment. The combination of trastuzumab with paclitaxel has longer survival than conventional cytotoxic chemotherapy only.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2023.41.16_suppl.e21599
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2023
detail.hit.zdb_id:
2005181-5
Permalink